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Dopamine (DA) plays a major role in motor and cognitive functions as well as in
reward processing by regulating glutamatergic inputs. In particular in the striatum the
release of DA rapidly influences synaptic transmission modulating both AMPA and NMDA
receptors. Several neurodegenerative and neuropsychiatric disorders, including Parkinson,
Huntington and addiction-related diseases, manifest a dysregulation of glutamate and DA
signaling. Here, we will focus our attention on the mechanisms underlying the modulation
of the glutamatergic transmission by DA in striatal circuits.
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INTRODUCTION
Dopamine (DA) is a catecholamine that acts as neuromodulator
by playing an important role in motor and cognitive functions as
well as in reward processing.
Our major understanding of the DA transmission derives
from studies of the midbrain DA system that comprehend
both Substantia Nigra pars compacta (SNc-A9) and Ventral
Tegmental Area (VTA—A10). The former is at the origin
of the nigrostriatal pathway where DA neurons project to
the dorsal striatum and play a central role in controlling
fine motor functions. Instead DA neurons within the VTA
form the mesostriatal pathway and project to the ventral
striatum (or Nucleus accumbens, NaC) exerting an important
role in reward processing (Paillé et al., 2010; Tritsch and
Sabatini, 2012). How does DA shape all these different
functions in the brain? In both circuitries, DA acts as a
neuromodulator regulating the glutamatergic inputs onto the
principal neurons and therefore controlling the striatal output.
More than 95% of striatal neurons are represented by Medium
Spiny Neurons (MSNs; Kreitzer, 2009) that form asymmetric
synapses with glutamatergic projections and symmetric contacts
at the DA inputs. Therefore, the activity of DA neurons
and the consequent release of DA in the proximity of the
synaptic cleft rapidly influences synaptic transmission, intrinsic
excitability and dendritic integration (Tritsch and Sabatini,
2012), partially explaining the different functions of DA
in the brain. Importantly DA can modulate glutamatergic
transmission by the convergence effect onto MSNs, by acting
on D2-R located presynaptcally on Glutamatergic inputs or by
modulating excitatory inputs onto GABAergic and Cholinergic
interneurons.
Interestingly, several neurodegenerative and neuropsychiatric
disorders, including Parkinson, Huntington and addiction-
related diseases, manifest a dysregulation of glutamate and DA
signaling within the striatum. In this review, we will focus our
attention on the mechanisms underlying the modulation of
the glutamatergic transmission by DA in the nigrostriatal and
mesostriatal circuitries (Figure 1).
NIGROSTRIATAL CIRCUIT
DA neurons of the SNc project to the dorsal striatum. This
structure is mainly populated by MSNs that are classified in
two populations according to their axonal projections and
DA receptor expression. DA receptor type 1 (D1R)-containing
MSNs form the direct pathway and send their axons to the
GABAergic output nuclei of the basal ganglia, the internal
segment of the Globus Pallidus (GPi) and the Substantia Nigra
pars reticulata (SNr), which in turn send their afferences to
the motor nuclei of the thalamus. DA receptor type 2 (D2R)-
containing MSNs constitute the indirect pathway and send their
axons to the external segment of the Globus Pallidus (GPe),
which in turn project to the glutamatergic neurons of the Sub-
Thalamic Nucleus (STN). STN neurons then send their axons to
the basal ganglia output nuclei (GPi and SNr) where they form
excitatory synapses on the inhibitory output neurons. Activation
of the direct and indirect pathway exerts an opposite effect
on movement: activation of the direct pathway disinhibits the
thalamocortical projections and leads to activation of the cortical
premotor circuits facilitating movements. The activation of the
indirect pathway instead inhibits the thalamocortical projection
neurons reducing the premotor drive and inhibiting movements
(Kreitzer and Malenka, 2008). Interestingly this model has been
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FIGURE 1 | Nigrostriatal and Mesostriatal circuits. Sagittal view of the excitatory inputs onto the nigrostriatal and mesostriatal circuits.
recently challenged and it has been proposed that the two
pathways are structurally and functionally intertwined (Dunah
and Standaert, 2001; Calabresi et al., 2014).
By acting on D1R or D2R, DA differently modulates the
activity of the direct and indirect pathway both controlling the
excitability of MSNs in the striatum and governing synaptic
plasticity at different glutamatergic inputs. The majority of
glutamatergic afferents onto the dorsal striatum originates
in the cortex and thalamus. While corticostriatal afferences
may carry motor and cognitive information, thalamostriatal
ones convey information for the reward saliency and the
wakefulness (Huerta-Ocampo et al., 2014). Despite this view,
both corticostriatal and thalamostriatal terminals form synaptic
contacts with D1 and D2 MSNs and the convergence of their
inputs suggests that they are similarly involved in activation of the
MSNs.
Profound functional differences in these pathways have
been found, suggesting input-dependent differences in synaptic
functions (Smeal et al., 2008). Future studies are needed to
investigate the input segregation onto the direct and indirect
striatal pathways and their functional implications.
MESOSTRIATAL CIRCUIT
This circuit originates in the VTA where DA neurons project to
D1 and D2 MSNs of the ventral striatum. Although the presence
of D1 and D2 MSNs in the ventral striatum is well established,
there are several evidences showing that projections from the NAc
may not be so segregated as for the dorsal striatum. Indeed, it has
been shown that both D1 and D2 MSNs project to the ventral
pallidum, while D1 MSNs can also directly project to the VTA
(Lu et al., 1998; Zhou et al., 2003; Smith et al., 2013). Despite
these differences, it is well established that D1 and D2 MSNs in
the NAc exhibit different electrophysiological properties (Paillé
et al., 2010; Pascoli et al., 2011b, 2014b) and respond differently to
VTA stimulation (Grueter et al., 2010; Paillé et al., 2010). Despite
this clear segregation of D1 and D2 containing MSN, it
should be mention the existence of a small population of
neurons containing both D1Rs and D2Rs (Matamales et al.,
2009).
Similarly to the nigrostriatal circuit, DA modulates and
integrates glutamatergic synaptic inputs from the prefrontal
cortex, the amygdala and the hippocampus. Interestingly,
different forms of synaptic plasticity have been described at
different excitatory inputs onto D1 and D2 MSNs suggesting that
specific pattern of neuronal activity coinciding with DA signal
are needed for specific reward-related behavioral outcomes (Paillé
et al., 2010; Pascoli et al., 2014b).
DA RECEPTORS AND SIGNALING PATHWAYS
DA transmission is mediated by Guanine nucleotide binding
Protein Coupled Receptors (GPCRs). They are metabotropic
receptors with seven transmembrane domains coupled to G-
proteins that lead to the formation of second messengers and
the activation or inhibition of subsequent signaling cascades.
Although five different DA receptors have been cloned so far, it
is possible to classify them in two major populations according
to their structures and their pharmacological properties: (a) D1-
like receptors (D1 and D5) which stimulate cAMP production;
and (b) D2-like receptors (D2, D3 and D4) which reduce the
intracellular cAMP levels. The ability of D1-like and D2-like
receptors to modulate in opposite directions the concentration of
cAMP, and thus the downstream signal transduction, depends on
their interaction with specific G proteins.
D1-like receptors are the most highly expressed DA receptor
in the brain, are mainly localized within the forebrain and,
compared to the D2-like family, have a highly conserved
sequence (Tritsch and Sabatini, 2012). Binding of DA with
D1-like receptors leads to an increase in the adenylyl cyclase
activity and a consequent rise in cAMP levels. This pathway
induces the activation of protein kinase A (PKA) and the
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FIGURE 2 | Molecular and functional changes at the glutamatergic
synapse in Parkinson and Huntington disease. The cartoon
illustrates the physiological glutamatergic corticostriatal synapse (left
panel) and the molecular and functional alterations at DA and NMDA
receptor level observed in experimental models of Parkinson and
Huntington disease (right panels).
phosphorylation of different substrates as well as the induction
of immediate early gene expression that contribute to the overall
D1R response (Beaulieu and Gainetdinov, 2011). DARPP-32
(DA and cAMP-regulated phosphoprotein, 32kDa) is one of
the most studied PKA substrates activated by DA and provides
a mechanism for integrating information at dopaminoceptive
neurons (Svenningsson et al., 2004). Via the control of
Protein Phosphatase-1 (PP-1), DARPP-32 regulates neuronal
excitability as well as glutamatergic transmission. Activation of
the cAMP/PKA/DARPP-32 pathway indeed increases the opening
of the L-type Ca2+ channels promoting the transition of MSNs
to a higher level of excitability (Vergara et al., 2003). At the same
time, the activation of this pathway promotes the phosphorylation
of both AMPARs and NMDARs providing a mechanism for the
direct control of glutamatergic transmission by DA signaling
(Snyder et al., 1998, 2005).
There are multiple modulatory effects following D2R activa-
tion. First of all, these receptors are coupled with Gi/o proteins
and their activation negatively modulates cAMP signaling,
reducing the phosphorylation of the downstream proteins (PKA
targets), such as DARPP-32. At the same time, activation of
D2R, via the Gβγ subunits, inhibits L-type Ca2+ channels and
activates G-protein-coupled Inwardly Rectifying potassium (K+)
channels (GIRK) causing a decrease of neuronal excitability and
a reduction in the synthesis and release of DA (Kebabian and
Greengard, 1971). Moreover D2Rs are also located presynatpically
onto the excitatory inputs where influence glutamate release
and on ChaT interneurons in the striatum where contribute to
reducing Ach release (Surmeier et al., 2007).
Interestingly, DA has a lower affinity for D1Rs compared to
D2Rs, pointing at a different effect on the direct and indirect
pathway during tonic or phasic DA release. Indeed, it has been
suggested that phasic release activates D1Rs to facilitate limbic
inputs while tonic release bidirectional activates D2Rs on PFC
inputs (Floresco et al., 2003; Goto and Grace, 2005; Goto et al.,
2007). It is important to consider the different effects of DA
change the functions of the brain regions that receive DA inputs.
Indeed, an altered DA modulation of the excitatory inputs onto
these regions plays an important role in the pathophysiology of
many neurological disorders (Goto et al., 2007).
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DA MODULATION OF NMDARs AND AMPARs
DA modulates the functioning of the glutamatergic synapse by
acting at different levels. The classical view indicates that DA
can regulate the activity of ionotropic glutamate receptors with
a reduction of AMPAR-evoked responses and an increase of
NMDAR-evoked responses (Cepeda et al., 1993; Levine et al.,
1996; Cepeda and Levine, 1998; Graham et al., 2009). In
particular, activation of D1R usually leads to potentiation of
NMDAR-dependent currents, while activation of D2R induces a
decrease of AMPAR-dependent responses. This view has a key
relevance in the striatum where dopaminergic terminals form
synaptic contacts at the neck of MSN spines, while the head
receives inputs from glutamatergic terminals (Surmeier et al.,
2007).
Interestingly, NMDARs in the corticostriatal synapse show
peculiar features. Indeed, even if GluN2B represents the
predominant regulatory subunit expressed in this brain area
(Dunah and Standaert, 2001), it has been proposed that GluN2A-
but not GluN2B-containing NMDARs induce a depression
of synaptic transmission that does not involve activation of
corticostriatal neurons but it is rather mediated NMDARs at
MSN synapses (Schotanus and Chergui, 2008a). Interestingly,
recent reports have suggested that GluN2A and GluN2B subunits
differentially contribute to the glutamatergic transmission in
striatal MSNs (Paoletti et al., 2008; Jocoy et al., 2011). While
genetic deletion or pharmacological blockade of GluN2A increase
D1R-mediated potentiation of NMDAR-dependent responses,
inhibition of GluN2B reduces this potentiation, suggesting a
counterbalance of their respective functions. Moreover, it has
shown that GluN2A subunits contribute mainly to NMDA
responses in D1-MSNs, whereas GluN2B subunits is more
involved in NMDA responses in D2R cells (Paoletti et al., 2008;
Jocoy et al., 2011).
Several studies have investigated the effect of D1R stimulation
on NMDAR subunit trafficking at the synaptic membrane.
Pharmacological activation of D1R enhances NMDARs surface
levels (Hallett et al., 2006; Paoletti et al., 2008) and NMDAR
localization in the synaptosomal membrane fraction through
stimulation of the tyrosine kinase Fyn (Dunah et al., 2004; Tang
et al., 2007). In more detail, it has been shown that treatment
with D1R agonist (SKF38393) leads to a significant decrease
of GluN2A-containing NMDARs and to a concomitant increase
in spine head width (Vastagh et al., 2012). Interestingly, co-
treatment of corticostriatal slices with GluN2A antagonist (NVP-
AAM077) and D1R agonist augmented the increase of dendritic
spine head width observed with SKF38393 alone. Conversely,
GluN2B antagonist (ifenprodil) blocked any morphological effect
induced by D1 activation (Vastagh et al., 2012). However, further
studies are still needed for a comprehensive understanding of the
specific role of GluN2A- vs. GluN2B-containing NMDARs in the
modulation of dendritic spine morphology at striatal MSNs.
BAC transgenic mice expressing EGFP in D1R- and D2R-
positive cells (Valjent et al., 2009) has recently been used to
carefully analyze DA-dependent modulation of MSNs within the
direct and indirect pathways (Cepeda et al., 2008). In agreement
with previous studies, D1R-dependent modulation of glutamate-
evoked responses was correlated with the activation of direct
pathway neurons. On the contrary, D2R-dependent reduction of
glutamate-evoked responses was specific to the indirect pathway
(André et al., 2010). Moreover, recent and advanced tools such
as optogenetics and sophisticated Ca2+ imaging have shown that
activation of D2 receptors decrease NMDAR-induced responses
by presynaptic modulation of glutamate release (Higley and
Sabatini, 2010).
Notably, several studies describing the co-existence of D1Rs
and NMDARs at striatal MSN synapses indicate the presence of
a possible direct molecular interaction between the two receptor
systems (Kung et al., 2007; Heng et al., 2009; Kruusmägi et al.,
2009; Jocoy et al., 2011; Vastagh et al., 2012). A direct interaction
between these two receptors was originally proposed by Lee
et al. (2002), who showed co-immunoprecipitation of D1R with
GluN1/GluN2A subunits of the NMDAR. This interaction is
not static, but is decreased by D1R activation (Lee et al., 2002;
Luscher and Bellone, 2008). In addition, disruption of D1R
interaction with GluN2A-containing NMDARs by interfering
peptides is sufficient to induce a modulation of NMDAR currents
thus suggesting a direct role for this receptor-receptor binding
in NMDA-transmission (Lee et al., 2002; Brown et al., 2010).
However, the issue is more complicated since in both striatal
neurons and transfected HEK293 cells, D1R directly interacts with
GluN1 subunit to form a constitutive oligomeric complex that is
recruited to the plasma membrane by the presence of GluN2B
subunit (Fiorentini et al., 2003). Moreover, this interaction
abolishes D1R internalization, a crucial adaptive response that
normally occurs upon agonist stimulation (Fiorentini et al.,
2003).
More recent studies have applied high-resolution single
nanoparticle live-imaging techniques to investigate the role of the
dynamic interaction between D1R and NMDAR at hippocampal
synapses (Ladepeche et al., 2013a). The prevention of the
physical interaction between D1R and GluN1 by interfering
peptide is able to fully abolished the synaptic stabilization
of D1R, thus suggesting that D1Rs are dynamically retained
at glutamatergic synapses through a mechanism requiring the
interaction with NMDAR (Ladepeche et al., 2013a). Moreover,
disruption of D1R/NMDAR complex increases NMDAR synaptic
content through a fast lateral redistribution of the receptors, and
favors long-term synaptic potentiation (Ladepeche et al., 2013b).
In particular, D1R activation reduces D1R/GluN1 interaction at
perisynaptic sites and allows the lateral diffusion of NMDARs
into the postsynaptic density where they support the induction of
Long-term potentiation (LTP; Argilli et al., 2008; Ladepeche et al.,
2013b).
D2-type DA receptors also interact with NMDARs. At the
postsynaptic density, D2Rs form a specific complex with the
NMDARs through the C-terminal domain of GluN2B subunit
(Liu et al., 2006). Interestingly, DA stimulation by cocaine
(i) enhances the D2R/GluN2B interaction; (ii) reduces the
association of CaMKII with GluN2B; (iii) lowers the CaMKII-
dependent phosphorylation of GluN2B (Ser1303); and (iv)
inhibits NMDA receptor-mediated currents in MSNs (Liu et al.,
2006).
DA can also modulate the activity of AMPARs leading to
a reduction of AMPAR-evoked responses (Cepeda et al., 1993;
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Levine et al., 1996; Cepeda and Levine, 1998; Bellone and
Lüscher, 2006; Engblom et al., 2008; Mameli et al., 2009;
Brown et al., 2010). Early studies performed in cultured neurons
showed that activation of D1R in striatal MSNs promotes the
phosphorylation of AMPARs by PKA as well as the potentiation of
current amplitude (Price et al., 1999). D2Rs antagonists increase
the phosphorylation of GluR1 at Ser845 without affecting the
phosphorylation at Ser831 (Håkansson et al., 2006). The same
effect is observed using eticlopride, a selective D2R antagonist.
On the contrary, D2R agonist quinpirole decreased GluR1
phosphorylation at Ser845 (Håkansson et al., 2006). Modulation
of DA receptors is also able to regulate AMPAR trafficking at the
synaptic membranes. In particular, treatment with D1R agonist
leads to an increase of AMPA receptor subunits surface expression
(Snyder et al., 2000; Gao et al., 2006; Vastagh et al., 2012).
DA MODULATION OF SYNAPTIC PLASTICITY
DA plays an important role in modulating long-term changes in
synaptic strength. One of the best-characterized forms of synaptic
plasticity in the striatum is the long-term depression (LTD). In
the dorsal and ventral striatum this form of plasticity requires
the concomitant activation of mGluR5 and voltage-gated calcium
channels and it is expressed by the release of endocannabinoids
(eCBs). eCBs act retrogradly onto their CB receptors and decrease
the probability of glutamate release (Robbe et al., 2002; Kreitzer
and Malenka, 2005).
Interestingly, this form of LTD depends upon the activation of
D2Rs, but whether it is controversial whether is only expressed
at glutamatergic inputs onto MSNs of the indirect pathway
of the dorsal striatum. Indeed, while eCB-LTD has been first
characterized in D2R MSNs of the dorsal striatum (Kreitzer and
Malenka, 2007), this form of plasticity has been described in
both D1R and DR2 striatal neurons of the direct and indirect
pathways in BAC transgenic mice (Wang et al., 2006). One
possible explanation for the expression of this form of LTD at
MNS synapses that do not express D2Rs is that, in both cell types,
D2R-dependence of LTD induction is not direct, but it rather
depends upon the activation of D2Rs in cholinergic interneurons
(Wang et al., 2006).
Long-term potentiation (LTP) at excitatory inputs onto MSNs
in the dorsal and ventral striatum is less characterized, and the
information that are available so far is even more controversial
compared to striatal LTD because of the variety of protocols used
to induce this form of plasticity by different laboratories. In the
dorsal striatum, LTP induction onto D1 MSNs depends on D1Rs,
while, in D2 MSNs, the same form of synaptic plasticity requires
the activation of adenosine A2R (Shen et al., 2008; Pascoli et al.,
2014a). In both the direct and indirect pathways, the activation
of D1Rs and A2Rs, and the concomitant activation of NMDARs
leads to the phosphorylation of DARPP-32 and MAPKs that
are involved in the expression of LTP (Calabresi et al., 1992,
2000; Kerr and Wickens, 2001; Surmeier et al., 2014). In the
ventral striatum, a protocol of High Frequency Stimulation (HFS)
induces a form of LTP that relies on the activation of D1Rs but
not D2Rs (Schotanus and Chergui, 2008b). Interestingly, previous
work showed that LTP is impaired by both D1 and D2 antagonists
suggesting that this form of LTP depends upon DA concentration
(Li and Kauer, 2004). A recent study, using cell identification,
reported that while HFS-LTP is induced in both D1 and D2 MSNs,
this form of LTP is blocked by cocaine treatment only in the
direct pathway (Pascoli et al., 2011b). The authors characterized
the induction and expression mechanisms of this LTP which
was reported to be NMDA and ERK pathway-dependent. Future
studies are required to investigate the mechanisms underlying LTP
in the indirect pathway, and to characterize this form of synaptic
plasticity in an input specific manner.
The role of DA in governing striatal plasticity has been
addressed by analyzing the mechanisms of Spike Time Dependent
Plasticity (STDP) in the dorsal striatum. In both D1 and D2
MSNs, synaptic plasticity follows Hebbian rules. LTP is indeed
induced when postsynaptic spiking follows synaptic activity
(positive timing), while LTD is favored when the order is
reversed (negative timing). Compared to other synapses, in
the dorsal striatum, DA plays important roles in determining
the sign of synaptic plasticity. In the direct pathway, positive
timing gives rise to LTP only when D1 are stimulated, otherwise
it leads to LTD. Instead, negative timing induces LTD when
D1Rs are not stimulated. In the indirect pathway, D2 signal is
necessary for LTD when the postsynaptic spiking is followed
by synaptic stimulation. When D2Rs are blocked and A2Rs are
stimulated, the same pairing protocol induces LTP (Shen et al.,
2008). Therefore, DA modulation in the dorsal striatum ensures
that the bidirectional synaptic plasticity follows the Hebbian
rules. Further investigation is needed to determine whether
these rules apply to all glutamatergic inputs and to the ventral
striatum too.
PARKINSON DISEASE
Parkinson’s disease (PD) physiopathology is linked to a
widespread degeneration of DA-releasing neurons of the
Substantia Nigra pars compacta (SNpc), with the loss of
DA reaching striatal projecting neurons (Obeso et al., 2010).
The degeneration of the nigrostriatal dopaminergic pathway
leads to significant morphological and functional changes in
the striatal neuronal circuitry, including modifications of the
corticostriatal glutamatergic synaptic architecture (Sgambato-
Faure and Cenci, 2012; Mellone and Gardoni, 2013) and the
consequent loss of striatal synaptic plasticity (Calabresi et al.,
2014). A very elegant study demonstrated the asymmetry of the
effect of DA denervation on the connectivity of striatonigral
and striatopallidal MSNs (Day et al., 2006). In particular, DA
depletion leads to a profound decrease in dendritic spines and
glutamatergic synapses on striatopallidal MSNs but not on
striatonigral MSNs (Day et al., 2006).
It was recently shown that distinct degrees of DA denervation
differentially affect the induction and the maintenance of two
distinct and opposite forms of corticostriatal synaptic plasticity
(Paillé et al., 2010). An incomplete (approximately 75%) nigral
denervation does not affect corticostriatal LTD in MSNs, which
is however abolished by a complete lesion. This result indicates
that a low although critical level of DA is required for this
form of synaptic plasticity. Conversely, an incomplete DA
denervation dramatically alters the maintenance of LTP in MSNs,
demonstrating a critical role of this form of synaptic plasticity
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in the early motor parkinsonian symptoms (Paillé et al., 2010).
In two different models of PD Shen et al. (2008) showed that in
D2R-expressing MSNs, LTP was induced not only by the usual
pairing protocol but also with a validated protocol known to
induce LTD. Conversely, in D1R-expressing MSNs a protocol
normally inducing LTP produces a robust form of LTD that was
sensitive to CB1 receptor block (Shen et al., 2008). Imbalances
between neural activity in the direct vs. the indirect pathway have
been indicated as a major event underlying severe motor deficits
observed in PD (Calabresi et al., 2014). In models of PD, eCB-
mediated LTD is absent but is rescued by treatment with D2R
receptor agonist or with inhibitors of eCB degradation (Kreitzer
and Malenka, 2007), thus indicating eCB-mediated depression of
indirect-pathway synapses as a critical player in the control of
motor behavior in PD.
Alterations of NMDAR subunit composition at MSNs
synapses have been reported to sustain this altered expression
of plasticity (Sgambato-Faure and Cenci, 2012; Mellone and
Gardoni, 2013). It is known that NMDARs are characterized
by GluN2A and GluN2B regulatory subunits in MSNs, being
GluN2B the most abundant (Dunah and Standaert, 2001).
Notably, changes in synaptic NMDAR GluN2A/GluN2B subunit
ratio in striatal MSNs correlate with the motor behavior
abnormalities observed in a rat model of PD (Picconi et al.,
2004; Gardoni et al., 2006; Mellone and Gardoni, 2013). In
particular, levels of GluN2B were specifically reduced in synaptic
fractions from fully-lesioned 6-OHDA rats when compared to
sham-operated rats in the absence of GluN2A alterations in the
same samples (Picconi et al., 2004; Gardoni et al., 2006; Paillé
et al., 2010). In addition, in the 6-OHDA model of PD, rats with a
partial lesion of the nigrostriatal pathway (about 75%) showed a
dramatic increase in the GluN2A immunostaining at the synapse
without any modifications of GluN2B (Paillé et al., 2010). Overall
these data indicate an increased GluN2A/GluN2B ratio at MSNs
synapses at different stages of DA denervation in experimental rat
models of PD. Accordingly, a cell-permeable peptide that interfers
with the interaction between GluN2A and the scaffolding protein
PSD-95 is able to reduce the synaptic levels of GluN2A-containing
NMDARs and to rescue the physiological NMDAR composition
and synaptic plasticity in MSNs (Paillé et al., 2010). Moreover,
stimulation of D1Rs by systemic administration of SKF38393
normalizes NMDAR subunit composition and improves motor
behavior in a model of early PD establishing a critical link between
a specific subgroup of DA receptors and NMDARs and motor
performances (Paillé et al., 2010).
Altogether, the emerging pathophysiological picture shows
that the strength of glutamatergic signals from the cortex to the
striatum might be dynamically regulated by the different degree of
DA denervation during the progression of the disease (Figure 2).
In fact, bidirectional changes in corticostriatal synaptic plasticity
are critically controlled by the degree of nigral denervation that
influences the endogenous DA levels and the assembly of striatal
NMDARs (Sgambato-Faure and Cenci, 2012).
HUNTINGTON DISEASE
Huntington’s disease (HD) is a progressive neurodegenerative
disease which is characterized by chorea, cognitive decline, and
psychiatric disturbances. Alterations in DA and DA receptor
levels in the brain contribute to the clinical symptoms of HD
(Spokes, 1980; Richfield et al., 1991; Garrett and Soares-da-Silva,
1992; van Oostrom et al., 2009). In particular, time-dependent
modifications of DA signaling are correlated to biphasic
alterations of the activity of the glutamatergic synapse (Cepeda
et al., 2003; Joshi et al., 2009; André et al., 2011a). In agreement
with this biphasic activity, Graham et al. (2009) demonstrated that
susceptibility to NMDAR-dependent excitotoxicity in HD mouse
models was correlated to the severity of their symptomatic stage.
On the one hand, HD mice at an early age display enhanced
sensitivity to excitotoxic NMDAR-dependent events compared to
wild-type animals. On the other hand, old symptomatic HD mice
are more resistant to NMDA-dependent neurotoxicity (Graham
et al., 2009).
Dysfunction and loss of striatal MSNs represent the
major neuropathological feature of the disease (Martin and
Gusella, 1986). Although the mechanisms explaining a selective
degeneration of MSNs in HD have not been addressed, several
reports correlated an abnormal functioning of both dopaminergic
and glutamatergic transmission to the induction of striatal MSNs
death (Charvin et al., 2005; Fan and Raymond, 2007; Tang et al.,
2007).
A decrease of D1R and D2R in striatum from postmortem
HD brains has been reported in several studies (Joyce et al.,
1988; Richfield et al., 1991; Turjanski et al., 1995; Suzuki et al.,
2001). In addition, a significant alteration of both D1R and D2R
density and function in the striatum has been described in HD
mouse models (Bibb et al., 2000; Ariano et al., 2002; Paoletti
et al., 2008; André et al., 2011b). Studies performed in knock-
in HD striatal cells showed that mutant huntingtin enhances
striatal cell death through activation of D1R but not D2R (Paoletti
et al., 2008). Particularly, pretreatment with NMDA increased
D1R-induced cell death of mutant but not wild-type cells thus
suggesting that NMDARs potentiate the vulnerability of HD
striatal cells to DA toxicity (Paoletti et al., 2008). Interestingly,
an aberrant Cdk5 activity is involved in the augmented sensitivity
of HD striatal cells to DA and glutamate inputs (Paoletti et al.,
2008). In agreement with these data, Tang et al. (2007) reported
that glutamate and DA act synergistically to induce elevated
Ca2+ signals and to induce apoptosis of MSNs in HD mice.
Again, these effects are selectively mediated by D1R and not
by D2Rs (Tang et al., 2007). However, a role for D2R in
mediating MSN degeneration has been put forward (Charvin
et al., 2005, 2008), thus raising the hypothesis that both activation
of D1R and D2R might contribute to glutamate/DA dependent
toxicity. More recently, André et al. (2011b) showed that, at
the early stage, glutamate release was increased onto D1R cells
while it was unaltered onto D2R cells in HD mice. Notably, at
the late stage, glutamate transmission was decreased onto D1R
cells only. Overall, this study suggests that more changes occur
in D1R cells than in D2R cells, at both presymptomatic and
symptomatic ages. Finally, in agreement with this study, Benn
et al. (2007) showed that the percentage of D2R-positive cells
are not modified with the phenotype or with age. However, it
must be taken into account that these results represent a clear
discrepancy with early studies indicating a higher vulnerability of
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D2R in HD (Reiner et al., 1988; Albin et al., 1992). Accordingly,
further studies are needed for a complete characterization and
understanding of D1R vs. D2R alterations in HD.
Changes in synaptic vs. extra-synaptic localization of
NMDARs are also crucial for neuronal survival in HD (Levine
et al., 2010). In particular, a selective increase of striatal GluN2B-
containing NMDARs in association with an early increase in
extrasynaptic NMDAR signaling has been described in different
HD animal models (Zeron et al., 2004; Milnerwood et al., 2010).
In addition, excitotoxicity mediated by GluN2B-containing
NMDARs exacerbated selective MSNs degeneration in a knockin
HD model (Heng et al., 2009).
DA and glutamate cross-talk seems to have a key role also
in aberrant synaptic plasticity which is observed in HD animal
models. DA-dependent LTP, but not LTD, in the dorsal striatum
is reduced in the R6/2 mouse model of HD (Kung et al.,
2007; Figure 2). Interestingly, the deficits in LTP and short-
term plasticity observed in animal models of HD are reversed by
treatment with the D1R agonist SKF38393 (Dallérac et al., 2011).
ADDICTION
Drug-evoked synaptic plasticity of glutamatergic synapses in
the mesocorticolimbic system has been largely implicated in
addictive behaviors (Luscher and Bellone, 2008) and DA
neurons of the VTA are the point of convergence at which
addictive drugs can alter the brain circuits (Brown et al.,
2010). Drug-evoked synaptic plasticity has been characterized
at excitatory input onto DA neurons of the VTA 24 h after
a single injection of addictive drugs (Ungless et al., 2001;
Bellone and Lüscher, 2006; Mameli et al., 2007; Yuan et al.,
2013). Interestingly, it is induced by activation of D1/D5Rs
and NMDARs (Ungless et al., 2001; Argilli et al., 2008) and it is
expressed by insertion of GluN3A-containing NMDARs (Yuan
et al., 2013) and GluA2-lacking AMPARs (Bellone and Lüscher,
2006). Moreover, it has been shown that the redistribution of
glutamatergic receptors induced by cocaine in the VTA depends
upon the action of cocaine on DA transporter (DAT) and that DA
neurons activity itself is sufficient to induce drug-evoked synaptic
plasticity at glutamatergic synapses (Brown et al., 2010). D1
signaling in the VTA is necessary for these adaptations suggesting
that the convergence of DAergic/glutamatergic signaling in the
VTA modifies the circuit at the synaptic level.
Interestingly, redistribution of glutamatergic transmission in
the VTA is permissive for the expression of drug-evoked plasticity
in the NAc and subsequent addictive behaviors. Indeed, deletion
of GluN1 selectively in the DA neurons of the VTA abolishes
both cocaine-evoked plasticity in the NAc (Engblom et al., 2008)
and prevent reinstatement of self-administration (Mameli et al.,
2009).
In the NAc, the convergence of DA and glutamate after
cocaine exposure contributes to addictive behaviors by the
facilitation of AMPAR trafficking at certain glutamatergic inputs.
Early studies have found that D1R stimulation increases GluA1
surface expression via PKA activation promoting further NMDA-
dependent synaptic plasticity (Sun et al., 2005, 2008; Gao et al.,
2006). Recently, the role of AMPAR trafficking in drug-evoked
synaptic plasticity and its link to behavioral adaptation has
been demonstrated. Indeed, insertion of GluA2-lacking (GluA1
homomeric) AMPARs has been shown both after incubation
of cocaine craving and cocaine self-administration at excitatory
input onto MSNs in the NAc (Conrad et al., 2008; Lee et al., 2013;
Ma et al., 2014; Pascoli et al., 2014b; Figure 3). Although these
studies show some discrepancies regarding the cell- and input-
specificity of Ca2+ permeable AMPAR insertion, the removal
FIGURE 3 | Synaptic changes at the glutamatergic synapses during cocaine seeking. The cartoon illustrates the physiological glutamatergic corticostriatal
and hippocampastriatal synapses (left panel) and the synaptic alterations at excitatory synapses onto MSNs during cocaine seeking (Right panel).
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of these receptors is an efficient method to revert addictive
behaviors (Loweth et al., 2014; Pascoli et al., 2014b). Altogether,
these studies indicate that the expression of addictive behaviors
depends upon the convergence of DA/glutamate signal and the
consequent changes in the efficacy and quality of excitatory
synaptic transmission.
Which are the mechanisms underlying the interactions
between the glutamate and the DA system in the NAc in drug
addiction? Many studies have shown that different behavioral and
molecular responses induced by cocaine rely on the D1R-NMDAR
interaction that regulates the activity of ERK pathways and control
gene expression, plasticity and behavior (Girault et al., 2007;
Bertran-Gonzalez et al., 2008; Pascoli et al., 2014a). Interestingly,
cocaine-induced activation of the ERK pathway is restricted to
D1 MSNs and depends upon the concomitant activation of
D1 and NMDARs. Moreover, direct blockade of ERK signaling
induced by cocaine prevents the expression of conditioned place
preference (CPP; Valjent et al., 2000), locomotor sensitization
(Valjent et al., 2006) and drug-evoked synaptic plasticity (Pascoli
et al., 2011b; Cahill et al., 2014). To confirm the role of
DA/glutamate interaction in cocaine-induced ERK activation, it
has also been shown that indirect inhibition of the ERK pathway
blocks addictive behaviors. Cocaine activates the tyrosine kinase
Fyn that, via phosphorylation of GluN2B, potentiates Ca2+ influx
through NMDARs and activates ERK signaling. Interestingly, the
inhibition of Fyn inhibits cocaine-induced ERK activation while
inhibition of GluN2B-containing NMDAR impairs locomotor
sensitization and CPP (Pascoli et al., 2011a). Moreover, the
blockade of the D1/GluN1 downstream pathways, although it
preserves the individual signaling, blocks both the D1-induced
potentiation of Ca2+ influx via NMDARs and the ERK activation.
As a consequence, behavioral sensitization is impaired (Cahill
et al., 2014).
CONCLUSIONS
Functional interactions between DA and glutamate receptors
modulate an incredible variety of functions in the brain and, when
abnormal, they contribute to numerous central nervous system
disorders. In particular, an integrated cross-talk between DA and
glutamate receptors plays a key role in motor control, cognition
and memory, neurodegenerative disorders, schizophrenia and
addictive behaviors. Accordingly, a huge number of studies,
described in the present review, have been performed aiming
at understanding the molecular and functional mechanisms
coordinating functions of glutamate and DA receptors. Hopefully,
a complete knowledge of dysregulation of glutamate and DA
signaling as in Parkinson, Huntington and addiction-related
diseases, could represent the first step for the identification and
setting up of novel therapeutical approaches for these brain
disorders.
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